AUM Biosciences Further Strengthens Advisory Board with Addition of Dr. Timothy Low

AUM Biosciences (AUM), a Singapore-based company officially announced today the addition of Dr. Timothy Low to its Board of Advisors. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.

Register Interest

About Timothy Low

Dr. Timothy Low is the Head of HealthCare Investment at Pavilion Capital and is a member of the Board of Directors at Farrer Park Hospital in Singapore.

Previously, Dr. Low was the CEO of Farrer Park Hospital, a private acute tertiary care institution within Singapore’s first fully integrated healthcare and hospitality complex, complete with a 5-Star Hotel, Hospital and Specialist Medical Centre. The hospital was awarded “Best New Hospital in Asia Pacific” and “Smart Hospital of the Year in Asia Pacific” in 2016 and 2017 respectively.

With over 30 years of tenure in both public and private sectors, Dr. Low is widely recognized as an outstanding medical expert who contributes strategically, with deep technical know-how and intuitive financial acumen. He is a passionate transformational leader, maximizing human assets to deliver exceptional experiences for customers. Dr. Low is a proven leader with a track-record of success with start-up ventures and operational turnarounds.

He was formerly CEO of Gleneagles Hospital, Singapore and an Asia Pacific Medical Affairs Senior Executive across Bio-Pharmaceutical, Medical Device and CRO industries at Shire/Takeda, Covidien/Medtronic, Schering Plough/MSD, Covance and GlaxoWellcome (now known as GSK).

He was awarded the “50 Most Talented Healthcare Leaders of Asia” as well as “Hospital Management Asia Excellence Award” in 2016. Dr. Low was named the “Best CEO of the Year” in Healthcare, Singapore in 2017. He was also conferred the “Icons of Healthcare” – Leading Healthcare Management Professional of the Year and Rare Disease Champion Provider of the Year in Asia Pacific, both in 2018. In 2019, he was recognized as the “Most Media Savvy Personality” by Global Health and Travel.

Dr. Low graduated with a Medical Degree from the National University of Singapore. He also attended the Singapore Management University (Asia Pacific Hospital Management) and graduated from the Stanford University – NUS Graduate School of Business Executive Program.

“We are delighted to have Dr. Timothy Low join our Board of Advisors. His extensive experience and recognized leadership will help guide AUM Biosciences in its next stage of development. It is truly a privilege to be working alongside Dr. Low” stated Mr. Vishal Doshi, CEO of AUM Biosciences.

“I am very excited to join AUM Biosciences Board of Advisors and look forward to guiding them on the next stage of their growth. AUM is a cutting-edge biotechnology company developing affordable cancer medicines including one that was first discovered in Singapore” stated Dr. Timothy Low.

Register Interest

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. AUM is dedicated to revolutionizing the existing inefficient drug development paradigm by harnessing the power of precision medicine and digitalisation. AUM focuses on early stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets. Led by a highly experienced management team with over 100 years of combined oncology drug development experience, AUM is disrupting the drug development paradigm by implementing a holistic approach to developing drugs. Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, pharmaceutical companies and clinicians globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. 

The company holds exclusive worldwide rights in all disease indications for 2 first-in-class composition of matter technologies. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR).

AUM001 is Phase II ready and AUM302 has a clear pathway to orphan drug designation. For more information, please visit

Register Interest